The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion failure at one year compared with provisional stenting (PS) in the treatment of true distal bifurcation lesions of the left main artery, according to a large-scale randomized trial.

James A. Brink, M.D., FACR, chair of the American College of Radiology (ACR) Board of Chancellors, met with the House Committee on Science, Space and Technology Subcommittee on Energy to urge more research on low-dose medical radiation effects to inform future safety practices. He also told the Committee that medical imaging and radiation oncology save lives.

November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strategy ...

Edwards Lifesciences Corp. announced new data demonstrating substantial economic advantages of the Edwards Sapien 3 transcatheter aortic heart valve for patients suffering from severe, symptomatic aortic stenosis (AS) who are at intermediate risk for open-heart surgery. Results of the economic analysis, which is the first-of-its-kind report on intermediate-risk patients, were presented as a late-breaking clinical trial at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

October 31, 2017 — The U.S. Food and Drug Administration (FDA) issued a warning to healthcare providers that interim ...

The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published new guidelines for the treatment of patients with ventricular arrhythmias and the prevention of sudden cardiac death.

Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally Invasive Annuloplasty) technology. The patient was enrolled in the first arm of the STTAR (Study of Transcatheter Tricuspid Annular Repair) clinical trial studying the safety and efficacy of MID's MIA device designed to eliminate or greatly reduce tricuspid regurgitation.

CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's ongoing clinical trial of its proprietary Cobra PzF NanoCoated Coronary Stent (NCS) with 14-day dual antiplatelet therapy (DAPT) in complex patients, such as those who are at high bleeding risk. The COBRA REDUCE trial is the world's first and only randomized control trial to assess 14-day DAPT after percutaneous coronary intervention (PCI), according to the company.